TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
TaiMed Biologics
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
Advancing CD4-targeted biologics for
long-acting HIV treatment and beyond
TaiMed is a commercial-stage biologics company building
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
on nearly two decades of CD4-targeted science to advance differentiated antibody therapies.
Our lead clinical program, TMB-365/380, is being developed as a long-acting HIV maintenance regimen
designed around durable viral suppression, broader applicability,
and greater clinical simplicity in real-world care.
Explore Our Science
Latest News
- TaiMed Biologics (4147) invited to participate in the TPEx–Fubon Securities Biotechnology Industry Forum To Showcase Long-Acting Biologics Pipeline and Global Commercialization Strategy
- TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan
- TaiMed Advances Long-Acting HIV Therapy Into Late-Stage Development
- TaiMed Biologics (4147) Announces First Patient in TMB-365/380 Phase 2b Trial Successfully Completes Fourth Dose; Sustained Viral Suppression Remains Consistent with Expectations, Supporting an Optimi
- aiMed Biologics (4147) Achieves Key Milestone for Trogarzo Launch in Taiwan; Partner Orient Pharma (4120) Secures TFDA Name Approval
ABOUT
Broadening the potential of long-acting HIV maintenance
TMB-365/380 is being developed as a complete, antibody-only maintenance regimen for virologically suppressed adults. Its complementary host-and-virus targeting strategy is designed to support durable disease control while reducing small-molecule backbone complexity and exploring the potential for broader real-world applicability.
PROOF POINTS
We are doing a couple of things you might be interested in
94%
Maintained HIV-1 RNA below 50 copies/mL through Week 24 in Phase 2a
0
Virologic failures among Phase 2a study completers
Q2M
Every-two-month dosing evaluated in Phase 2a and Phase 2b
Biologics development experience that extends beyond our own pipeline
TaiMed's biologics development and manufacturing capabilities support both our internal programs and selected external partners. Our CDMO team provides integrated services across process development, analytical development, formulation, cGMP manufacturing, and regulatory support.
Long-acting HIV is not one-size-fits-all
Fewer doses can matter, but meaningful innovation in HIV maintenance therapy depends on more than dosing interval alone. As people with HIV live longer and care becomes more complex, the field must also consider efficacy, safety, treatment eligibility, polypharmacy and drug-drug interactions, resistance, clinical flexibility, and fit with ongoing care. TaiMed is developing antibody-based approaches with these realities in mind.
合作夥伴
中裕新藥與相關生技醫療機構合作，持續研發促進人民福祉之技術
展覽資訊及活動紀錄
TaiMed HQ
- TEL：02-26580058
- TIME：8:00AM-18:00PM
- E-mail：ir@taimedbio.com
- Add：3F.,NO.607,Ruiguang Rd.,Neihu Dist.,Taipei City 11492,Taiwan(R.O.C.)
Hsinchu Branch Office
- TEL：03-6212355
- TIME：8:00AM-18:00PM
- ADD：No. 18, Ln. 15, Shengyi 5th Rd., Zhubei City, Hsinchu County, Taiwan (R.O.C.)
- Contact CDMO Service
TaiMed / Taimedbiologics / Clinical Development of Anti-HIV Medications / Trogarzo® / TaiMed biologics cdmo / cdmo services / HIV / cGMP Facility
256 bit SSL Encryption
Recommend using Chrome, Firefox, Safari latest version of the browser.
Designed by MIRACLEWeb Design
Contact CDMO Service